XNASNAII
Market cap26mUSD
Jan 10, Last price
4.21USD
1D
-0.23%
1Q
-10.98%
Jan 2017
-62.74%
Name
Natural Alternatives International Inc
Chart & Performance
Profile
Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States, Europe, Asia, and internationally. The company operates in two segments, Private-Label Contract Manufacturing, and Patent and Trademark Licensing. It offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. The company also provides strategic partnering services, such as customized product formulation, clinical studies, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, packaging and delivery system design, and regulatory review. In addition, it sells beta-alanine ingredient under the CarnoSyn and SR CarnoSyn names. The company manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. Natural Alternatives International, Inc. was founded in 1980 and is headquartered in Carlsbad, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | 2016‑06 | 2015‑06 | |
Income | ||||||||||
Revenues | 113,796 -26.11% | 154,015 -9.91% | 170,966 -4.23% | |||||||
Cost of revenue | 124,230 | 152,826 | 159,907 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (10,434) | 1,189 | 11,059 | |||||||
NOPBT Margin | 0.77% | 6.47% | ||||||||
Operating Taxes | (2,247) | 1,033 | 2,947 | |||||||
Tax Rate | 86.88% | 26.65% | ||||||||
NOPAT | (8,187) | 156 | 8,112 | |||||||
Net income | (7,217) -386.16% | 2,522 -76.46% | 10,712 -0.52% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | (221) | (1,503) | (5,503) | |||||||
BB yield | 0.63% | 3.55% | 8.56% | |||||||
Debt | ||||||||||
Debt current | 4,890 | 2,760 | 302 | |||||||
Long-term debt | 103,063 | 49,583 | 53,587 | |||||||
Deferred revenue | ||||||||||
Other long-term liabilities | 881 | 1,326 | 1,462 | |||||||
Net debt | 95,972 | 38,207 | 31,603 | |||||||
Cash flow | ||||||||||
Cash from operating activities | (1,497) | 7,019 | 11,866 | |||||||
CAPEX | (3,017) | (13,524) | (26,488) | |||||||
Cash from investing activities | (3,017) | (13,467) | (26,458) | |||||||
Cash from financing activities | 2,891 | (1,781) | 4,292 | |||||||
FCF | (31,392) | (8,862) | (15,037) | |||||||
Balance | ||||||||||
Cash | 11,981 | 13,604 | 21,833 | |||||||
Long term investments | 532 | 453 | ||||||||
Excess cash | 6,291 | 6,435 | 13,738 | |||||||
Stockholders' equity | 73,037 | 80,191 | 79,449 | |||||||
Invested Capital | 137,476 | 114,219 | 107,912 | |||||||
ROIC | 0.14% | 8.54% | ||||||||
ROCE | 0.99% | 9.00% | ||||||||
EV | ||||||||||
Common stock shares outstanding | 5,871 | 5,878 | 6,155 | |||||||
Price | 6.02 -16.39% | 7.20 -31.03% | 10.44 -37.97% | |||||||
Market cap | 35,343 -16.48% | 42,318 -34.14% | 64,259 -40.15% | |||||||
EV | 131,315 | 80,525 | 95,862 | |||||||
EBITDA | (5,787) | 5,439 | 15,224 | |||||||
EV/EBITDA | 14.81 | 6.30 | ||||||||
Interest | 361 | 451 | 83 | |||||||
Interest/NOPBT | 37.93% | 0.75% |